IO Biotech Announces Late-Breaking Oral Presentation of Phase 2 Clinical Melanoma Data Including Complete Response (CR) Rate of 45 Percent - Seite 2

"These early results are extremely encouraging and point toward a significant advantage of adding the vaccine to standard anti-PD1 therapy," said Professor Inge Marie Svane, MD, Director at Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital Herlev, Denmark. "Not only have we seen almost twice as many patients benefitting from the treatment as expected, but it is also important to note that the combination was very well tolerated by the patients."

"We are very pleased that the MM1636 study is selected as a late-breaking abstract at ESMO," said Mai-Britt Zocca, PhD, Chief Executive Officer and founder at IO Biotech. "There is a high unmet need for a more effective treatment for melanoma patients, and our data demonstrate clearly our anticipated hypothesis of our T-win compounds to add additional efficacy to anti-PD1 treatment without any observed safety concerns."

About MM1636 trial
The MM1636 trial is an investigator-initiated trial at the Copenhagen University Hospital, Herlev and enrolled 30 patients with metastatic melanoma. In this Phase 2 clinical trial, patients are receiving the anti programmed death 1 (PD-1) antibody nivolumab in combination with a multi antigen vaccine, IO102 and IO103, as first line treatment. Patients are being treated with nivolumab every second week as long as there is a clinical benefit or no adverse events prohibiting further treatment. IO102 and IO103 are given from the start of administration of nivolumab and every second week for the first six vaccines and thereafter every fourth week up to one year. The trial objectives are to assess safety, immune response in blood and biopsies as well as efficacy.

About IO102 and IO103
IO102 is a first-in-class, second-generation immune modulatory vaccine containing a single Indoleamine 2,3-dioxygenase (IDO) derived peptide sequence designed to engage and activate IDO specific human anti-regulatory T-cells.

IO103 is a first-in-class, immune modulatory vaccine containing a single PD-L1-derived peptide designed to engage and activate PD-L1 specific human anti-regulatory T-cells.  

Both compounds are based on IO Biotech's proprietary T-win technology platform which enables the identification of compounds with a dual mechanism of action targeting and directly killing immunosuppressive cells and tumor cells while indirectly activating other T-effectors, leading to strong anti-tumor responses.  The company's compounds are administered as "off-the-shelf" subcutaneous injections, distinguishing these treatments from many immuno-oncology therapies.